Pralatrexate

Systematic (IUPAC) name
N-(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid
Identifiers
CAS number	146464-95-1
ATC code	none
PubChem	148121
Chemical data
Formula	C23H23N7O5
Mol. mass	477.47 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Intravenous

Pralatrexate (rINN), also known as 10-propargyl-10-deazaaminopterin, common name PDX, is a drug candidate being studied for the treatment of cancer. PDX is a folate analog inhibitor of dihydrofolate reductase. As of August 2008^[update], it is undergoing Phase II clinical trials for the treatment of Hodgkin and non-Hodgkin lymphoma (including T-cell lymphoma), non-small cell lung cancer (NSCLC), and bladder cancer.

Results in non-small cell lung cancer appear promising.^[1]

Accelerated approval and orphan drug status was granted on September 24, 2009 by The US Food and Drug Administration (FDA) for pralatrexate injection (Folotyn, Allos Therapeutics, Inc) as a single agent for the treatment of relapsed or refractory peripheral T-cell lymphoma. (2)

[edit] References

1. ^ Krug LM, Azzoli CG, Kris MG, et al. (June 2003). "10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer". Clin. Cancer Res. 9 (6): 2072–8. PMID 12796370. http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=12796370. 

(2)http://www.cancer.gov/cancertopics/druginfo/fda-pralatrexate

[edit] External links

• Clinical trials of pralatrexate at ClinicalTrials.gov
• Allos Therapeutics Information on PDX

This pharmacology-related article is a stub. You can help Wikipedia by expanding it. v • d • e